Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

GlobeNewswire October 13, 2021

ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer

GlobeNewswire September 30, 2021

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

GlobeNewswire September 15, 2021

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

GlobeNewswire August 5, 2021

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

GlobeNewswire August 4, 2021

ObsEva to Present at Upcoming Investor Conferences

GlobeNewswire August 3, 2021

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

GlobeNewswire July 27, 2021

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

GlobeNewswire July 2, 2021

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting

GlobeNewswire June 30, 2021

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting

GlobeNewswire June 24, 2021

ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021

GlobeNewswire June 10, 2021

ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021

GlobeNewswire June 2, 2021

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

GlobeNewswire May 31, 2021

ObsEva Announces Proposed Changes to the Composition of its Board of Directors

GlobeNewswire May 25, 2021

ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

GlobeNewswire May 20, 2021

ObsEva Announces First Quarter 2021 Financial Results and Business Update

GlobeNewswire May 6, 2021

ObsEva appoints Clive Bertram as Chief Commercial Officer

GlobeNewswire May 6, 2021

ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021

GlobeNewswire April 30, 2021

ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants

GlobeNewswire April 27, 2021